ClinicalTrials.gg

Program

HRS-8427

A development code. Also written as “HRS-8427 injection plus furosemide”.

In Jiangsu HengRui Medicine's pipeline, Cefiderocol derivatives. Its studies are mostly in Pneumonia, Bacterial · Pyelonephritis · Gram-Negative Bacterial Infections, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Aug 22, 20246 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine60 open or runningphase 3since Aug 22, 2024Aug 22, 2024none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-8427, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2024First study: phase 3 study in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)First studyNCT06569056 · 579 enrolled · China
  2. Feb 19, 2025Phase 2 study in Hospital-acquired Bacterial Pneumonia (HABP)NCT06841731 · 120 enrolled · China
  3. Jun 24, 20253 phase 1 studiesNCT07049107, NCT07049562, NCT07073157
  4. Jul 8, 2025Phase 1 study in Gram-Negative Bacterial InfectionsNCT07070375 · 33 enrolled · China
  5. Sep 30, 2026Primary completion moved from 2026-02 to 2026-09-22Date moved laterphase 2 · +7 months · NCT06841731

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cefiderocol derivatives”the company's pipeline, read by Claude · source

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07070375Gram-Negative Bacterial Infections · China1CompletedAug 23, 202333
NCT07073157Health Volunteer · China1CompletedAug 15, 202524
NCT07049562Healthy Cninese Adult Male · China1CompletedJun 18, 20256
NCT07049107Health Volunteer · China1CompletedJul 21, 202514
NCT06841731Hospital-acquired Bacterial Pneumonia (HABP) · China2CompletedSep 22, 2026120
NCT06569056Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) · China3CompletedSep 1, 2026579

How it is read

Names in the registry

  • “HRS-8427”, 5 entries
  • “HRS-8427 injection plus furosemide”, 1 entry

Codes read as this program: HRS8427.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.